Koichi Akashi

US Patent:

6465247, Oct 15, 2002

Filed:

Jun 29, 2000

Appl. No.:

09/607529

Inventors:

Irving L. Weissman - Redwood City CA
David Jeffrey Traver - West Roxbury MA
Koichi Akashi - Palo Alto CA

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12N 506

US Classification:

435325, 424 932, 424 937, 435 2, 435354, 435355, 435372

Abstract:

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor ); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

US Patent:

6761883, Jul 13, 2004

Filed:

Sep 17, 2001

Appl. No.:

09/956279

Inventors:

Irving L. Weissman - Redwood City CA
David Jeffrey Traver - West Roxbury MA
Koichi Akashi - Palo Alto CA
Markus Gabriel Manz - Palo Alto CA
Toshihiro Miyamoto - Menlo Park CA

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A01N 6300

US Classification:

424 931, 424 937, 435325, 435366, 435372, 435391, 435405, 435 2

Abstract:

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7R, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

US Patent:

6908763, Jun 21, 2005

Filed:

Aug 22, 1997

Appl. No.:

08/918537

Inventors:

Koichi Akashi - Chestnut Hill MA, US
Motonari Kondo - Redwood City CA, US
Irving L. Weissman - Redwood City CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12N005/02
C12N005/06
C12N005/08
C12N015/87

US Classification:

435325, 435 71, 435354, 435355, 435363, 435372, 435374, 435455

Abstract:

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the isolation and culture of this common lymphoid progenitor cell (CLP). The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor α); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. The murine cells are also characterized as expressing low levels of sca-1 (Ly-6E and Ly-6A). The CLPs are predominantly cycling, blast cells. These cells give rise to B cells, T cells and natural killer cells, as evidenced by their growth and differentiation in vitro and in vivo.

US Patent:

7297329, Nov 20, 2007

Filed:

Mar 29, 2005

Appl. No.:

11/093951

Inventors:

Koichi Akashi - Chestnut Hill MA, US
Irving L. Weissman - Redwood City CA, US
Motonari Kondo - Redwood City CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A01N 65/00

US Classification:

424 931, 435325

Abstract:

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the isolation and culture of this common lymphoid progenitor cell (CLP). The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor α); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. The murine cells are also characterized as expressing low levels of sca-1 (Ly-6E and Ly-6A). The CLPs are predominantly cycling, blast cells. These cells give rise to B cells, T cells and natural killer cells, as evidenced by their growth and differentiation in vitro and in vivo.

US Patent:

7300760, Nov 27, 2007

Filed:

Dec 15, 2003

Appl. No.:

10/737576

Inventors:

Irving L. Weissman - Redwood City CA, US
David Jeffrey Traver - West Roxbury MA, US
Koichi Akashi - Boston MA, US
Markus Gabriel Manz - Palo Alto CA, US
Toshihiro Miyamoto - Menlo Park CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

G01N 33/53
C12N 5/00
C12N 5/02

US Classification:

435 71, 435325, 435372, 435373, 435374

Abstract:

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7Rα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

US Patent:

7618654, Nov 17, 2009

Filed:

Oct 18, 2007

Appl. No.:

11/874841

Inventors:

Irving L. Weissman - Redwood City CA, US
David Jeffrey Traver - West Roxbury MA, US
Koichi Akashi - Palo Alto CA, US
Markus Gabriel Manz - Palo Alto CA, US
Toshihiro Miyamoto - Menlo Park CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 35/28
G01N 33/53

US Classification:

424577, 435 71

Abstract:

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. Tηε χελλ ενιχημεντ μετηoδσ εμπλoψεαγεντσ τηατ σπεχαλλψεψoγνιζε Tηψ-1; ανδIΛ-7 Pα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

US Patent:

58211080, Oct 13, 1998

Filed:

Apr 7, 1995

Appl. No.:

8/418534

Inventors:

Koichi Akashi - Palo Alto CA
Irving Weissman - Redwood City CA

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C12N 1585
G01N 3353
A61K 39395

US Classification:

4352402

Abstract:

A subpopulation in the CD4. sup. + 8. sup. + (DP) thymic blast population is identified that is the precursor for thymic T cells. All such progenitors are c-kit. sup. +. The c-kit. sup. + subset expresses lower levels of CD4 and CD8 than the large and small DP c-kit- cells. These DP. sup. int c-kit. sup. + cells differentiate to thymic T cells rapidly on heterogenous thymic stromal cell cultures. Similar maturation takes place in vivo over 4 days. A method for isolating the cells which are c-kit. sup. + and which express intermediate or low levels of CD4+/CD8+ is also disclosed.